Upgrade to SI Premium - Free Trial

Pfizer (PFE) Announces Tofacitinib Phase 3 Met Primary Efficacy Endpoints in Psoriatic Arthritis

April 5, 2016 7:04 AM
Pfizer Inc. (NYSE: PFE) announced top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles